CINECA IRIS Institutional Research Information System

AGATE, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.323
EU - Europa 5.509
AS - Asia 2.207
SA - Sud America 298
AF - Africa 274
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 3
Totale 14.624
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.177
DE - Germania 2.092
IT - Italia 1.057
CN - Cina 860
SE - Svezia 817
SG - Singapore 735
GB - Regno Unito 483
BG - Bulgaria 271
BR - Brasile 260
AT - Austria 230
RU - Federazione Russa 197
HK - Hong Kong 194
CI - Costa d'Avorio 146
CA - Canada 133
TR - Turchia 130
SN - Senegal 104
VN - Vietnam 102
FI - Finlandia 86
UA - Ucraina 74
IN - India 65
FR - Francia 45
CH - Svizzera 32
NL - Olanda 25
BE - Belgio 23
JP - Giappone 20
IR - Iran 19
PL - Polonia 11
AU - Australia 10
CZ - Repubblica Ceca 10
IE - Irlanda 9
KR - Corea 9
IL - Israele 8
IQ - Iraq 8
MA - Marocco 8
AZ - Azerbaigian 7
SK - Slovacchia (Repubblica Slovacca) 7
TW - Taiwan 7
AR - Argentina 6
CL - Cile 6
EE - Estonia 6
MX - Messico 6
PH - Filippine 6
PK - Pakistan 6
VE - Venezuela 6
CO - Colombia 5
EC - Ecuador 5
GR - Grecia 5
ID - Indonesia 5
LT - Lituania 5
BD - Bangladesh 4
RO - Romania 4
UY - Uruguay 4
UZ - Uzbekistan 4
ZA - Sudafrica 4
ES - Italia 3
KE - Kenya 3
MY - Malesia 3
PE - Perù 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
BJ - Benin 2
BO - Bolivia 2
BY - Bielorussia 2
DK - Danimarca 2
DZ - Algeria 2
EG - Egitto 2
HU - Ungheria 2
KG - Kirghizistan 2
PT - Portogallo 2
SA - Arabia Saudita 2
SV - El Salvador 2
TH - Thailandia 2
TN - Tunisia 2
A1 - Anonimo 1
AL - Albania 1
DO - Repubblica Dominicana 1
EU - Europa 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
JO - Giordania 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
MK - Macedonia 1
MN - Mongolia 1
NG - Nigeria 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
PY - Paraguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 14.624
Salva come PNG Salva come JPEG
Città #
Ashburn 670
Woodbridge 658
Chandler 580
Santa Clara 540
Fairfield 490
Ann Arbor 403
Milan 359
Singapore 311
Houston 304
Sofia 271
Shanghai 260
Seattle 214
Vienna 209
Wilmington 208
New York 196
Hong Kong 182
Cambridge 181
Beijing 180
Abidjan 146
Princeton 138
Boardman 128
London 115
Ottawa 109
Lawrence 106
Dakar 104
Florence 92
Jacksonville 91
Serra 87
Frankfurt am Main 80
Medford 80
Nanjing 58
Pisa 58
Rome 57
Izmir 56
Bremen 52
Dearborn 52
Istanbul 52
Des Moines 51
Boulder 50
Dong Ket 49
San Diego 37
Munich 36
Redmond 34
Fuzhou 33
Los Angeles 33
Lancaster 28
Bern 27
Düsseldorf 25
Redwood City 25
Helsinki 24
Ogden 24
Brussels 22
Nanchang 20
Washington 20
Guangzhou 18
Quanzhou 18
São Paulo 17
Jiaxing 16
Kunming 16
Toronto 15
Dallas 14
Hefei 14
Jüchen 13
Nuremberg 13
Changsha 12
Ningbo 11
Norwalk 11
Zhengzhou 11
Chiesina Uzzanese 10
Lauterbourg 10
Lucca 10
Nürnberg 10
Shenyang 10
Vicopisano 10
Wuhan 10
Brno 9
Chengdu 9
Kocaeli 9
Pune 9
Rio de Janeiro 9
Tianjin 9
Amsterdam 8
Belo Horizonte 8
Falkenstein 8
Hangzhou 8
Hebei 8
Philadelphia 8
Phoenix 8
Scandicci 8
Bratislava 7
Dublin 7
Jinan 7
Tokyo 7
Chicago 6
Falls Church 6
Grafing 6
Portsmouth 6
Xiamen 6
Baku 5
Brasília 5
Totale 8.870
Salva come PNG Salva come JPEG
Nome #
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line. 219
Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. 213
Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma 212
ALL-TRANS RETINOIC ACID TREATMENT INHIBITS THE GROWTH OF RARb mRNA EXPRESSING THYROID CANCER CELL LINES BUT DOES NOT RE-INDUCE THE EXPRESSION OF THYROID SPECIFIC GENES 209
The presence of a tall cells>10% in a classical variant of papillary thyroid carcinoma (CV-PTC) makes its aggressiveness similar to that of tall cell variant (TCV-PTC) 207
Ciglitazone induces cell growth inhibition in a medullary thyroid carcinoma cell line (TT) likely by an increase of PPARgamma expression 194
In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer 192
Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients 191
Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line 187
Identification of a novel point mutation in the RET gene (Ala883Thr), which is associated with medullary thyroid carcinoma phenotype only in homozygous condition 183
Medullary thyroid cancer treated with vandetanib: predictors of longer and durable response 183
Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies 181
CLINICAL IMPACT OF RET GENETIC SCREENING IN THE MANAGEMENT OF MEDULLARY THYROID CARCINOMA (MTC) PATIENTS: 20 YEARS OF EXPERIENCE 178
Targeted Therapy in Thyroid Cancer: State of the Art 178
Ret Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center 175
Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: Clinical implications derived from the first prospective randomized controlled single institution study 172
Treatment of advanced thyroid cancer with targeted therapies: Ten years of experience 171
Changing Trend of Thyroglobulin Antibodies in Patients with Differentiated Thyroid Cancer Treated with Total Thyroidectomy Without ¹³¹I Ablation 171
A complex MEN2 syndrome, a mixture of 2B and 2A, associated with a new RET germiline deletion. 171
All-trans Retinoic Acid treatment inhibits the growth of RARb mRNA expressing thyroid cancer cell lines but does not re-induce the expression of thyroid specific genes 169
RET point mutations in Thyroid Carcinoma 163
RET/PTC rearrangements in Belarus, Ukrainian and Russian pos Chernobyl thyroid tumors 162
Low-Risk Differentiated Thyroid Cancer with BRAFV600E mutation is more difficult to cure than negative cases: a 5-year follow-up study. 161
Hypertension, nausea, anorexia and weight loss were significantly associated with better progression-free survival in patients with radioiodine-Refractory Differentiated Thyroid Carcinoma treated with Lenvatinib 161
Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal 160
RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) 159
Prevalence of papillary thyroid cancer (PTC) in patients affected by medullary thyroid cancer (MTC) 154
Thyroglobulin Antibodies (TgAb) Titer Spontaneously Decrease Until The Negativization Or Stabilization In Most Of Cases Of Papillary Thyroid Microcarcinoma (mPTC) Treated With Total Thyroidectomy But Not Ablated With 131I 154
Active surveillance in papillary thyroid microcarcinomas is feasible and safe: experience at one single Italian center 148
Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid 146
Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients 146
null 146
Active Surveillance In Papillary Thyroid Microcarcinomas (PMCS): A 2 Years Follow Up (FU) At A Single Center 146
Lung recurrence of papillary thyroid cancer diagnosed with antithyroglobulin antibodies after 10 years from initial treatment. 145
Lenvatinib therapy in progressive, radioiodine-refractory, differentiated thyroid carcinoma: analysis of 74 cases followed in a single centre 145
Thyroid autoantibodies and thyroid function in subjects exposed to Chernobyl fallout during childhood: evidence for a transient radiation-induced elevation of serum thyroid antibodies without an increase in thyroid autoimmune disease. 144
Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico. 144
Successo terapeutico di Lenvatinib in seconda linea in un caso di carcinoma follicolare della tiroide avanzato 144
Thyroid consequences of the Chernobyl nuclear accident. 142
Il carcinoma tiroideo: nuove prospettive terapeutiche. 142
, Descrizione della prima mutazione omozigote germinale di RET (Ala883->Thr) che non determina l'insorgenza del carcinoma midollare della tiroide in condizioni di eterozigosi 141
New and old knowledge on differentiated thyroid cancer epidemiology and risk factors. 141
Retinoic acid receptor beta2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2'-deoxycytidine treatment 136
Role of Thyroglobulin, Neck Ultrasound, Thyroglobulin Antibodies Trend and Diagnostic Whole Body Scan in the Management of Differentiated Thyroid Cancer Patients with Persistent Thyroglobulin Antibodies 136
Fifty years after the first description, the MEN 2B syndrome diagnosisis still late: description of two recent cases 136
Recombinant human TSH (rhTSH) in 2009: new perspectives in diagnosis and therapy 135
Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer 133
ROLE OF THYROID REMNANT ABLATION WITH LOW ACTIVITY OF 131I IN PATIENTS WITH LOW AND INTERMEDIATE RISK PAPILLARY THYROID CARCINOMA (PTC). 132
Correlation between early and 24th hour 131-I uptake in post-surgical thyroid remnant evaluation 129
Twenty years of lesson learning: How does the RET genetic screening test impact the clinical management of medullary thyroid cancer? 129
Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer. 128
The stage of differentiated thyroid cancer at diagnosis is significantly more advanced in children than in adolescent 127
In vitro studies of retnoic acid treatment of human anaplastic, poorly differentiated papillary, follicular and medullary thyroid cancer cell lines 125
Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma 125
Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma 124
Advantages and disadvantages of prophylactic central compartment lymph node dissection for differentiated thyroid cancer: the first randomized controlled study from a single referral center. 124
5 YEARS FOLLOW UP OF THYROGLOBULIN (TG), THYROGLOBULIN ANTIBODIES (TGAB) AND NECK ULTRASOUND (US) IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA (MPTC) TREATED WITH TOTAL THYROIDECTOMY BUT NOT ABLATED WITH 131I 124
A rare adverse event (AE) in a group of radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients in therapy with lenvatinib. 124
Thyroid incidentaloma 123
null 122
BRAFV600E mutation is an indipendent predictive prognostic factor for persistent/recurrent disease in low risk differentiated Thyroid cancer patients: a 5 year follow-up study. 120
Less than 2% of the low- and intermediate-risk differentiated thyroid cancers show distant metastases at post-ablation whole-body scan 120
Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow up of differentiated thyroid cancer patients 119
Thyroglobulin changes are highly dependent on TSH in low-risk DTC patients not treated with 131I 118
Lenvatinib treatment in the real clinical practice of progressive, radioiodine-refractory differentiated thyroid carcinoma: analysis of a big series followed in a single center 116
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 115
null 114
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments 114
Studi in vitro del trattamento con acido retinico di linee di carcinoma tiroideo umano anaplastico, poco differenziato, follicolare e midollare 112
5 Years Follow Up Of Thyroglobulin (Tg), Thyroglobulin Antibodies (Tgab) And Neck Ultrasound (Nus) In Patients With Papillary Thyroid Microcarcinoma (Mptc) Treated With Total Thyroidectomy But Not Ablated With 131I 110
Recombinant Human Thyrotropin Stimulation Thyroglobulin (rhTSH-Tg) test can identify false serum tg due to heterophilic antibodies in differentiated thyroid cancer (DTC) patients 109
No difference in the outcome of metastatic thyroid cancer patients when using recombinant or endogenous TSH 108
null 107
Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up 106
null 105
The Thymic Hyperplasia (TH) And Biochemical Persistence Of Disease In Patients With Differentiated Thyroid Carcinoma (DTC) 105
Influence of Lymphocytic Thyroiditis at Histology and Serum Thyroglobulin Autoantibodies on the Course of Papillary Thyroid Carcinoma 104
Correlation Between The Presence Of Macrophages And Braf V600e Mutation In Different Variants Of Well Differentiated Papillary Thyroid Cancer 103
null 103
The Mutation Profile Of Medullary Thyroid Carcinoma Can Be Different In Primary And Metastatic Tissues 102
Clinical Impact Of Ret Genetic Screening Of In The Management Of Medullary Thyroid Carcinoma (MTC) Patients: 20 Years Of Experience 102
Radioiodine remnant ablation (RRA) Impact on the dynamic risk of restratification in the short-term follow-up of patients with differentiated thyroid cancer (DTC). 99
Predictive Value Of High Sensitive Thyroglobulin Assay (USTG) And Neck Ultrasonography (US) At The Time Of Remnant Ablation On Lt-4 Therapy In Patients With Low And Intermediate Risk Differentiated Thyroid Cancer (DTC) 95
Significato prognostico della mutazione di BRAF in pazienti affetti da carcinoma papillare della tiroide con follow-up di 20 anni. 94
MON-490 Calcitonin-Based Thyroidectomy Is a Safe Approach in Patients with Germline RET Mutation and Permits to Delay Surgery in Children 93
null 86
Thyroid autoimmunity, thyroglobulin autoantibodies and thyroid cancer prognosis 85
Fenotipo misto MEN2A/MEN2B da nuova mutazione germinale di RET: prima descrizione clinico-genetica e iconografia 85
null 84
Delayed radioiodine remnant ablation (RRA) does not impact on the outcome of intermediate risk for recurrence differentiated thyroid cancer patients (IR-DTC). 84
Thyroid cancers: From surgery to current and future systemic therapies through their molecular identities 84
Ca19.9 positivity and doubling time are prognostic factors of mortality in patients with advanced medullary thyroid cancer with no evidence of structural disease progression according to RECIST 82
Impact of the Stimulation method Used for 131-Therapy in Patients With Differentiated Thyroid Cancer. 81
OR21-01 Pre-Operative Calcitonin Value as a Predictive Factor of Cancer Related Death in Sporadic Medullary Thyroid Carcinoma 79
Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? 79
A novel fusion RET/PTC3 involving NCOA4 and RET genes in a pediatric case of Papillary Thyroid Carcinoma 75
The outcome of metastatic differentiated thyroid cancer is similar in patients prepared for 131-I therapy with recombinant TSH or Hypothyroidism. 75
Follicular (FVPTC) VS Classical (CVPTC) variant of papillary thyroid cancer: correlation of the outcome after 12 years of follow up. 74
Active surveillance in ret gene carriers belonging to families with multiple endocrine neoplasia 74
Non thyroidal second primary malignancies in differentiated thyroid cancer patients: is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? 73
Totale 13.255
Salva come PNG Salva come JPEG
Categoria #
all - tutte 43.275
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 43.275
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020407 0 0 0 0 0 0 0 0 0 0 374 33
2020/2021912 154 39 143 28 49 84 47 54 57 82 45 130
2021/20221.310 34 46 22 101 284 169 37 56 67 69 89 336
2022/20232.398 280 390 203 186 209 246 44 171 476 21 157 15
2023/20241.601 161 174 220 110 214 283 114 52 28 22 71 152
2024/20253.036 47 157 44 268 487 429 303 219 473 542 67 0
Totale 14.881